Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Gains from Investment Securities: 2011-2024

Historic Gains from Investment Securities for Mimedx Group (MDXG) over the last 11 years, with Dec 2024 value amounting to $2.6 million.

  • Mimedx Group's Gains from Investment Securities fell 24.55% to $83,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 12.91%. This contributed to the annual value of $2.6 million for FY2024, which is 1472.02% up from last year.
  • As of FY2024, Mimedx Group's Gains from Investment Securities stood at $2.6 million, which was up 1,472.02% from $168,000 recorded in FY2023.
  • Mimedx Group's Gains from Investment Securities' 5-year high stood at $4.8 million during FY2021, with a 5-year trough of $168,000 in FY2023.
  • Its 3-year average for Gains from Investment Securities is $1.3 million, with a median of $1.2 million in 2022.
  • As far as peak fluctuations go, Mimedx Group's Gains from Investment Securities slumped by 85.88% in 2023, and later soared by 1,472.02% in 2024.
  • Mimedx Group's Gains from Investment Securities (Yearly) stood at $2.3 million in 2020, then surged by 103.56% to $4.8 million in 2021, then crashed by 74.95% to $1.2 million in 2022, then plummeted by 85.88% to $168,000 in 2023, then spiked by 1,472.02% to $2.6 million in 2024.